![](/img/cover-not-exists.png)
Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
Ishii, Takahiro, Kawazoe, Akihito, Sasaki, Akinori, Mishima, Saori, Kentaro, Sawada, Nakamura, Yoshiaki, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, YoshinoVolume:
12
Journal:
Therapeutic Advances in Medical Oncology
DOI:
10.1177/1758835920942377
Date:
January, 2020
File:
PDF, 841 KB
2020